PL2125899T3 - Rokownicze biomarkery bezpieczeństwa nerek i panele biomarkerowe do monitorowania funkcji nerek - Google Patents

Rokownicze biomarkery bezpieczeństwa nerek i panele biomarkerowe do monitorowania funkcji nerek

Info

Publication number
PL2125899T3
PL2125899T3 PL08718189T PL08718189T PL2125899T3 PL 2125899 T3 PL2125899 T3 PL 2125899T3 PL 08718189 T PL08718189 T PL 08718189T PL 08718189 T PL08718189 T PL 08718189T PL 2125899 T3 PL2125899 T3 PL 2125899T3
Authority
PL
Poland
Prior art keywords
kidney function
biomarker signatures
renal safety
monitor kidney
predictive
Prior art date
Application number
PL08718189T
Other languages
English (en)
Inventor
Gerard Maurer
Frank Dieterle
Elias Perentes
Frank STÄDTLER
ANDRé CORDIER
Andreas Mahl
Jacky Vonderscher
Daniel Wahl
Olivier Grenet
Daniel Robert Roth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2125899T3 publication Critical patent/PL2125899T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL08718189T 2007-03-26 2008-03-25 Rokownicze biomarkery bezpieczeństwa nerek i panele biomarkerowe do monitorowania funkcji nerek PL2125899T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90809407P 2007-03-26 2007-03-26
EP08718189A EP2125899B1 (en) 2007-03-26 2008-03-25 Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
PCT/EP2008/053504 WO2008116867A1 (en) 2007-03-26 2008-03-25 Predictive renal safety biomarkers and biomarker signatures to monitor kidney function

Publications (1)

Publication Number Publication Date
PL2125899T3 true PL2125899T3 (pl) 2013-04-30

Family

ID=39325830

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08718189T PL2125899T3 (pl) 2007-03-26 2008-03-25 Rokownicze biomarkery bezpieczeństwa nerek i panele biomarkerowe do monitorowania funkcji nerek

Country Status (15)

Country Link
US (2) US8609812B2 (pl)
EP (12) EP2479565A3 (pl)
JP (2) JP5450375B2 (pl)
CN (2) CN103399155A (pl)
AU (1) AU2008231738B2 (pl)
BR (1) BRPI0809432A2 (pl)
CA (1) CA2681792A1 (pl)
DK (1) DK2125899T3 (pl)
ES (4) ES2397484T3 (pl)
HR (1) HRP20130127T1 (pl)
PL (1) PL2125899T3 (pl)
PT (1) PT2125899E (pl)
RU (1) RU2519148C2 (pl)
SI (1) SI2125899T1 (pl)
WO (1) WO2008116867A1 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100068265A (ko) 2007-08-29 2010-06-22 에이전시 포 사이언스, 테크놀로지 앤드 리서치 미용 및 약제용의, 에센셜 오일을 함유하는 당질계 계면활성제 마이크로에멀젼
EP2743702B1 (en) 2008-08-28 2017-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5947544B2 (ja) 2008-08-29 2016-07-06 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CN102246038B (zh) * 2008-10-21 2014-06-18 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
MX2011004174A (es) * 2008-10-21 2011-09-27 Astute Medical Inc Metodos y composiciones para diagnosis y prognosis de lesion renal e insuficiencia renal.
WO2010054389A1 (en) * 2008-11-10 2010-05-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20110097850A (ko) * 2008-11-22 2011-08-31 아스튜트 메디컬 인코포레이티드 신손상 및 신부전의 진단 및 예후 예측을 위한 방법 및 조성물
BRPI1007443B8 (pt) 2009-01-28 2021-07-27 Bio Preventive Medicine Corp método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo
AU2010210540B2 (en) * 2009-02-06 2015-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and failure
JP5567600B2 (ja) * 2009-02-06 2014-08-06 メタボロン インコーポレイテッド 薬剤の肝毒性の判定
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2012525570A (ja) * 2009-04-30 2012-10-22 エフ．ホフマン−ラ ロシュ アーゲー 腎臓損傷の心臓及び糖尿病に基づく原因の識別のための手段及び方法
US20120118737A1 (en) * 2009-07-02 2012-05-17 Harald Mischak Method And Markers For Diagnosing Acute Renal Failure
CA2770259A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting obstructive uropathy and associated disorders
CN102576011B (zh) 2009-08-07 2014-09-17 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的组合物和方法
NZ628085A (en) 2009-11-07 2015-12-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2514821B1 (en) * 2009-12-17 2017-09-06 School Juridical Person Kitasato Institute Cystatin C, antibody
NZ702527A (en) 2009-12-20 2016-07-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2585184T3 (es) 2010-02-05 2016-10-04 Astute Medical, Inc. Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
AU2011220413B2 (en) * 2010-02-26 2015-07-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
CA3067107C (en) 2010-06-03 2022-07-12 Idexx Laboratories, Inc. Markers for renal disease
CA2804297A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ703055A (en) 2010-06-23 2016-07-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5830329B2 (ja) * 2010-09-28 2015-12-09 国立大学法人 岡山大学 腎障害の新規マーカー
EP3249402A1 (en) * 2010-10-07 2017-11-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102147413A (zh) * 2010-12-08 2011-08-10 武汉生之源生物科技有限公司 一种小粒径匀相溶胶颗粒型胱抑素c测定试剂盒及其制备方法
CN102353782A (zh) * 2010-12-31 2012-02-15 上海华谷生物技术有限公司 抗人肾损伤分子1的体外诊断试剂盒及检测方法
CN102243241A (zh) * 2011-04-07 2011-11-16 武汉生之源生物科技有限公司 一种匀相溶胶颗粒型中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒及其制备方法
EA201490105A1 (ru) * 2011-07-09 2014-07-30 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
JP2014529073A (ja) * 2011-08-26 2014-10-30 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US20130062516A1 (en) * 2011-09-09 2013-03-14 Hsien-Shou Kuo Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample
WO2013067420A1 (en) * 2011-11-03 2013-05-10 Tumlin James A Acth for treatment of kidney disease
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
GB201210587D0 (en) * 2012-06-14 2012-08-01 Belfast Health And Social Care Trust Predictive biomarker
EP3572809A1 (en) * 2012-07-23 2019-11-27 Astute Medical, Inc. Methods for diagnosis of sepsis
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104280477B (zh) * 2014-11-03 2016-03-30 天津中医药大学 内源性小分子物质在快速检测肝毒性方面的应用
US11037070B2 (en) * 2015-04-29 2021-06-15 Siemens Healthcare Gmbh Diagnostic test planning using machine learning techniques
EP3316159A4 (en) 2015-06-25 2019-08-14 Advanced Telecommunications Research Institute International PREDICTIVE EQUIPMENT BASED ON A SYSTEM ASSOCIATED WITH SEVERAL INSTITUTIONS AND PREDICTION PROGRAM
US20180265914A1 (en) * 2015-08-31 2018-09-20 Hitachi Chemical Co., Ltd. Molecular methods for assessing post kidney transplant complications
WO2017040520A1 (en) 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing urothelial disease
EP4005598A1 (en) * 2016-03-29 2022-06-01 Karydo Therapeutix, Inc. Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
WO2017170803A1 (ja) 2016-03-29 2017-10-05 株式会社国際電気通信基礎技術研究所 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
WO2017216325A1 (en) 2016-06-17 2017-12-21 F. Hoffmann-La Roche Ag In vitro nephrotoxicity screening assay
CN106126972B (zh) * 2016-06-21 2018-10-02 哈尔滨工业大学 一种用于蛋白质功能预测的层级多标签分类方法
US11353465B2 (en) 2017-01-12 2022-06-07 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on C—C motif chemokine ligand 14 measurement
WO2018145117A1 (en) 2017-02-06 2018-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RU2687256C1 (ru) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией
CN111647670A (zh) * 2019-03-04 2020-09-11 中国医学科学院药物研究所 一种与肾病综合征相关的肠道菌属Faecalitalea及其应用
RU2761730C1 (ru) * 2020-12-25 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ дифференциальной диагностики уремического панкреатита и деструктивного панкреатита у пациентов, получающих заместительную почечную терапию - программный гемодиализ
RU2761732C1 (ru) * 2020-12-26 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ дифференциальной диагностики уремического псевдоперитонита и перитонита у пациентов, получающих заместительную почечную терапию - программный гемодиализ
RU2761725C1 (ru) * 2020-12-26 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ дифференциальной диагностики уремического псевдоперитонита и перитонита у пациентов, получающих заместительную почечную терапию - программный гемодиализ
RU2761733C1 (ru) * 2020-12-28 2021-12-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ дифференциальной диагностики уремического панкреатита и деструктивного панкреатита у пациентов, получающих заместительную почечную терапию - программный гемодиализ
CN115469026B (zh) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途
CN118777488B (zh) * 2024-09-13 2025-01-28 中日友好医院(中日友好临床医学研究所) 代谢标志物在制备监测pb肾毒性产品中的应用及制品

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013877A1 (en) * 1995-10-12 1997-04-17 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
WO1999015904A1 (en) * 1997-09-26 1999-04-01 University Of Washington Methods and compositions for diagnosing renal pathologies
CA2386895C (en) * 1999-10-13 2008-07-15 Masao Miwa Method of the diagnosis of renal disorder, hemolytic-uremic syndrome and intestinal hemorrhagic escherichia coli infection
RU2180965C1 (ru) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Способ дифференциальной диагностики заболеваний почек
WO2002006537A2 (en) * 2000-07-13 2002-01-24 Curagen Corporation Methods of identifying renal protective factors
WO2003031967A1 (fr) * 2001-10-02 2003-04-17 Ikagaku Co., Ltd. Kits de diagnostic de maladies renales
WO2004005934A2 (en) * 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
EP1616184B2 (en) * 2003-03-27 2018-05-30 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury
WO2004108964A1 (en) * 2003-06-04 2004-12-16 Agency For Science, Technology And Research Differentially regulated hepatocellular carcinoma genes and uses thereof
UA88879C2 (en) * 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
JP2007533005A (ja) * 2004-04-07 2007-11-15 ジーン ロジック インコーポレイテッド 肝毒性分子モデル
CA2589291A1 (en) * 2004-09-21 2006-06-01 University Of Manitoba Method of detecting kidney dysfunction
GB0507838D0 (en) * 2005-04-18 2005-05-25 Epsom & St Helier University H A method of measuring the glomerular filtration rate of an human or animal patient, a self-use kit for providing blood samples for use in measuring glomerular
US8372886B2 (en) * 2005-12-22 2013-02-12 Kiacta Sarl Treatment of renal disorders, diabetic nephropathy and dyslipidemias
EP2469279A1 (en) * 2006-03-11 2012-06-27 The Board Of Trustees Of The Leland Stanford Junior University Cystatin C, lysozyme and beta-2-microglobulin as biomarker for peripheral artery disease
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2008057806A1 (en) * 2006-11-01 2008-05-15 Vermillion, Inc. A panel of biomarkers for peripheral arterial disease

Also Published As

Publication number Publication date
EP2479573A2 (en) 2012-07-25
EP2479572A3 (en) 2012-09-26
EP2479566A3 (en) 2012-09-26
US20140171335A1 (en) 2014-06-19
EP2479572B1 (en) 2014-12-24
EP2479568A2 (en) 2012-07-25
EP2479568B1 (en) 2015-01-07
ES2532221T3 (es) 2015-03-25
EP2479572A2 (en) 2012-07-25
EP2479565A3 (en) 2012-09-26
WO2008116867A1 (en) 2008-10-02
EP2479567A3 (en) 2012-09-26
US8609812B2 (en) 2013-12-17
HRP20130127T1 (hr) 2013-03-31
CN103399155A (zh) 2013-11-20
EP2479564A2 (en) 2012-07-25
ES2532229T3 (es) 2015-03-25
US20100143956A1 (en) 2010-06-10
JP2010522871A (ja) 2010-07-08
PT2125899E (pt) 2013-01-24
CN101679525B (zh) 2013-06-19
EP2479570A2 (en) 2012-07-25
EP2479564A3 (en) 2012-09-26
BRPI0809432A2 (pt) 2014-09-09
EP2479568A3 (en) 2012-09-26
EP2479570A3 (en) 2012-09-26
RU2519148C2 (ru) 2014-06-10
EP2479574A2 (en) 2012-07-25
ES2397484T3 (es) 2013-03-07
EP2479566B1 (en) 2015-01-07
JP2014074721A (ja) 2014-04-24
AU2008231738A1 (en) 2008-10-02
EP2479569A2 (en) 2012-07-25
EP2479574A3 (en) 2012-09-26
EP2125899B1 (en) 2012-11-14
EP2125899A1 (en) 2009-12-02
EP2479566A2 (en) 2012-07-25
EP2479573A3 (en) 2012-09-26
ES2532220T3 (es) 2015-03-25
JP5450375B2 (ja) 2014-03-26
EP2479571A3 (en) 2012-09-26
CA2681792A1 (en) 2008-10-02
EP2479567A2 (en) 2012-07-25
EP2479565A2 (en) 2012-07-25
AU2008231738B2 (en) 2012-09-27
EP2479569A3 (en) 2012-09-26
CN101679525A (zh) 2010-03-24
RU2009139295A (ru) 2011-05-10
EP2479571A2 (en) 2012-07-25
DK2125899T3 (da) 2013-02-11
SI2125899T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
SI2125899T1 (sl) Napovedni renalni varnostni biomarkerji in biomarkerske signature za monitoring delovanja ledvic
IL216720A (en) Biological markers for assessing kidney disease
IL223419A0 (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
EP2373999A4 (en) NEW BIOMARKERS
GB0715171D0 (en) Sample processor
EP2542696A4 (en) Theranostic BIOMARKERS
ZA200908660B (en) Determining pressure
PT2460076T (pt) Análise de arquivo executável portátil
GB0701444D0 (en) Detecting analytes
HU0900688D0 (en) Portable emergency bridge
GB0810709D0 (en) Biomarkers for lupus
GB0900944D0 (en) Portable winch assembly
EP2393934A4 (en) DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
WO2012033999A3 (en) Biomarkers for predicting kidney and glomerular pathologies
ZA201105184B (en) Biomarker
GB0807214D0 (en) Biomarkers
DK2142905T3 (da) Biomarkørnormalisering
GB0722068D0 (en) Predictive test
DE502008002439D1 (de) Tragbare Rettungseinheit für Katasstrophenfälle
GB0821912D0 (en) Biomarkers
GB0724163D0 (en) Syphills detection reagent
GB0706284D0 (en) Methods for assessing renal function
GB0708064D0 (en) Biomarker
GB0700425D0 (en) High discriminating power biomarker diagnosing
GB0719611D0 (en) Data-processing